Treatment planning and doses analysis in the case of stage IIIB Non-Small Cell Lung Cancer (NSCLC)

Rizki Amaliya, Ajeng Hefdea, Fithrotun Nisa, Retno Kurniya, Fathul Jannah, Isfina Uniatunada, Aditya Prayugo Hariyanto, Fakhrusy Rizqy Ramadhan, Endarko*

*Corresponding author for this work

Research output: Contribution to journalConference articlepeer-review

Abstract

The second most frequently diagnosed cancer (11.4%) is lung cancer and the leading cause of cancer death (18%). Radiation planning is a stage in radiation treatment. The purpose of radiation planning is to provide the maximum dose to the target tumor and minimize the dosage received by the organ at risk (OAR). Therefore, it is necessary to make a treatment plan, and dose analysis was to determine radiation characteristics using a 3D Slicer. This study used three patient data on stage IIIB (large-cell) Non-Small Cell Lung Cancer obtained from The Cancer Imaging Archive (TCIA). This research uses 3D Slicer software. Relative Electron Density (RED) was obtained from the segment statistics module and radiation planning using the radiotherapy module. The study analyzes the Relative Electron Density, the target volume, the OAR, and homogeneity with the reference. The mean values of RED in the spinal cord, left lung, right lung, esophagus, and GTV-1 were 1.148, 0.244, 0.231, 0.629, and 0.691, respectively. The iso levels have values above 95% and less than 100%. The obtained radiation dose by organs at risk in all patients is still below the tolerance limit of the recommendation. The HI values of the three IDs are homogeneous.

Original languageEnglish
Article number020001
JournalAIP Conference Proceedings
Volume2858
Issue number1
DOIs
Publication statusPublished - 16 Aug 2023
Event11th International Conference on Theoretical and Applied Physics: The Spirit of Research and Collaboration Facing the COVID-19 Pandemic, ICTAP 2021 - Virtual, Online, Indonesia
Duration: 27 Oct 202128 Oct 2021

Fingerprint

Dive into the research topics of 'Treatment planning and doses analysis in the case of stage IIIB Non-Small Cell Lung Cancer (NSCLC)'. Together they form a unique fingerprint.

Cite this